Clinical Trial Update: A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period [Phase 2]

View source ↗

Summary

Phase 2 study assessing venetoclax in combination with a covalent BTK inhibitor for first-line chronic lymphocytic leukemia to achieve deep, durable remissions …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Venclexta (venetoclax)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING